SCHEMBL1079871

SCHEMBL1079871

Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1-c1cc2cnc(NC(C)C)nc2c(-c2cncnc2)c1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 9/20 0.54
LCK P06239 8/20 0.54
KDR P35968 7/20 0.54
JAK3 P52333 4/20 0.54
BRAF P15056 3/20 0.54
TEK Q02763 2/20 0.54
KIT P10721 6/20 0.51
SRC P12931 4/20 0.51
DDR2 Q16832 5/20 0.48
SYK P43405 2/20 0.47
ABL1 P00519 3/20 0.46
BCR P11274 2/20 0.46
DDR1 Q08345 2/20 0.46
BTK Q06187 2/20 0.45
TYK2 P29597 1/20 0.45
MAPK8 P45983 1/20 0.45
MAPK9 P45984 1/20 0.45
MAPK10 P53779 1/20 0.45
RAF1 P04049 1/20 0.45
CSF1R P07333 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1078725 0.91 LCK (0.56) MAPK14LCKKDRJAK3BRAF
SCHEMBL1076762 0.90 LCK (0.54) MAPK14LCKKDRJAK3BRAF
SCHEMBL1077822 0.90 MAPK14 (0.54) MAPK14LCKKDRJAK3BRAF
SCHEMBL1149207 0.88 KDR (0.52) MAPK14LCKKDRJAK3BRAF
SCHEMBL1077406 0.88 BRAF (0.44) MAPK14LCKKDRJAK3BRAF
SCHEMBL1149256 0.88 LCK (0.64) MAPK14LCKKDRJAK3BRAF
SCHEMBL1082249 0.83 LCK (0.66) MAPK14LCKKDRJAK3BRAF
SCHEMBL1079626 0.82 BRAF (0.44) MAPK14LCKKDRJAK3BRAF
SCHEMBL1079435 0.82 LCK (0.61) MAPK14LCKKDRJAK3BRAF
SCHEMBL1149064 0.82 LCK (0.65) MAPK14LCKKDRJAK3BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2269993-B1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2013-02-27 EP disclosed
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-17 US disclosed
EP-2269993-A1 2-AMINOQUINAZOLINE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2011-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE H1-2, H1-3, H1-0 MAPK14 2338/4885LCK 3187/4885KDR 896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.